Category: Include on Menu
-
Evoke Pharma shares surge as new GIMOTI patent added to FDA Orange Book
Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) jumped 19% on Thursday after the company announced that a new patent for its GIMOTI nasal spray has been included in the FDA’s Orange Book. The specialty pharmaceutical firm, which develops treatments for gastrointestinal conditions, revealed that U.S. Patent No. 12,377,064—covering the use of GIMOTI (metoclopramide) nasal spray for…
-
Thoma Bravo to take Dayforce private in $12.3 billion cash deal
Dayforce (NYSE:DAY) has agreed to be acquired by Thoma Bravo in a deal valued at $12.3 billion, in an all-cash transaction that will make the company privately held. Under the finalized terms, Dayforce shareholders will receive $70 per share, representing a 32% premium over the stock’s unaffected price prior to the announcement. The deal also…
-
Boeing shares climb amid reports of potential 500-aircraft deal with China
Shares of Boeing (NYSE:BA) jumped 2.5% Thursday morning after Bloomberg reported that the aerospace company is in advanced discussions to sell up to 500 planes to China. Such an order would mark a major rebound in Boeing’s Chinese sales, which have been largely dormant since 2017. Sources familiar with the talks say Boeing and Chinese…
-
McCormick to Boost Stake in Mexican Unit with $750 Million Purchase
McCormick & Company (NYSE:MKC) announced plans to acquire an additional 25% stake in McCormick de México from Grupo Herdez (USOTC:GUZOF) for $750 million, increasing its ownership in the Mexican subsidiary to 75%. The deal, which is expected to close in early 2026, implies an acquisition multiple of roughly 12 times projected 2025 EBITDA plus annual…
-
Modivcare Stock Crashes 40% Following Chapter 11 Bankruptcy Filing
Shares of Modivcare Inc. (NASDAQ:MODV) tumbled 40% in premarket trading Thursday after the healthcare services firm revealed it had entered Chapter 11 bankruptcy proceedings. The announcement came late Wednesday, with the company confirming it had filed for protection under Chapter 11 as part of a plan to restructure its balance sheet. As part of the…
-
Bilibili Stock Slips as Q2 Results Fail to Excite Despite Return to Profitability
Bilibili Inc. (NASDAQ:BILI) delivered its first quarterly profit in years during the second quarter of 2025, but investors were not swayed, sending the company’s shares down 3.5% in pre-market trading on Thursday. The video-streaming and gaming platform reported adjusted earnings of RMB 1.29 per share, ahead of the analyst consensus of RMB 1.20. Revenue came…
-
Full Truck Alliance Stock Falls Over 4% as Brokerage Fee Changes Cloud Outlook
Full Truck Alliance Co. Ltd. (NYSE:YMM) reported strong second-quarter results on Thursday that topped Wall Street estimates, but shares still fell more than 4% in pre-market trading after the company warned that upcoming changes to its freight brokerage business could weigh on transaction volumes. The digital freight platform posted adjusted earnings of $1.27 per ADS,…
-
Canadian Solar Shares Slide Over 10% After Q2 Earnings Miss Forecasts
Canadian Solar Inc. (NASDAQ:CSIQ) saw its stock tumble more than 10% in pre-market trading Thursday after reporting second-quarter results that fell far short of Wall Street expectations, despite posting stronger-than-expected gross margins. The solar energy and renewable technology firm disclosed an adjusted net loss of $0.53 per share, missing analyst consensus by a wide margin…
-
Meta Pauses AI Hiring After Heavy Spending, WSJ Reports
Meta Platforms (NASDAQ:META) has pressed pause on new hires within its artificial intelligence division after months of aggressive recruitment, according to a Wall Street Journal report published Wednesday. The freeze reportedly began last week and coincides with a broader shake-up of the company’s AI operations. In addition to halting external hiring, the restructuring restricts current…
-
DiamiR Biosciences Gains New York State Approval for APOE Genotyping Test, Expanding Alzheimer’s Risk Screening
DiamiR Biosciences Corp., a developer of blood-based diagnostics for brain health, and Aptorum Group Limited (NASDAQ:APM), a clinical-stage biopharmaceutical firm, announced that New York State’s Department of Health has approved DiamiR’s APOE Genotyping Test under the Clinical Laboratory Evaluation Program (CLEP). The regulatory milestone allows the test to be offered through DiamiR’s CLIA-certified and CAP-accredited…